CCR3 and neoplasm: Flow cytometry analysis of tumor, blood, spleen, and bone marrow (BM) samples demonstrated that anti-CCR3 antibody administration depleted most circulating CD45+CD11b+Gr-1loF4/80+Siglec-F+MHC-II- eosinophils (Figure 4B left and middle and Figure S4B).